Genetics and pathogenesis of inflammatory bowel disease, Nature, vol.474, pp.307-324, 2011. ,
Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes, Proc Natl Acad Sci U S A, vol.107, pp.18132-18139, 2010. ,
The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins, Sci Transl Med, vol.3, pp.106-106, 2011. ,
Engineering lactococci and lactobacilli for human health, Curr Opin Microbiol, vol.16, issue.3, pp.278-83, 2013. ,
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines, Microb Cell Fact, vol.10, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01189725
Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update, FEMS Microbiol Lett, vol.344, pp.1-9, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01019086
Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria, Nat Rev Microbiol, vol.6, pp.349-62, 2008. ,
Actobiotics as a novel method for cytokine delivery, Ann N Y Acad Sci, vol.1182, pp.135-180, 2009. ,
Therapeutic drug delivery by genetically modified Lactococcus lactis, Ann N Y Acad Sci, vol.1072, pp.176-86, 2006. ,
Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy, Cancer, vol.119, pp.4268-76, 2013. ,
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, Science, vol.289, pp.1352-1357, 2000. ,
Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10, Nat Biotechnol, vol.21, pp.785-794, 2003. ,
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease, Clin Gastroenterol Hepatol, vol.4, pp.754-763, 2006. ,
Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis, Gastroenterology, vol.140, pp.1272-82, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00552947
Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, vol.117, pp.636-683, 2007. ,
Protease-activated receptor-2 activation: a major actor in intestinal inflammation, Gut, vol.57, pp.1222-1231, 2008. ,
Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis, Sci Transl Med, vol.4, pp.158-144, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01204261
Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-beta1 under the control of dietary xylan 1, Inflamm Bowel Dis, vol.17, pp.1925-1960, 2011. ,
Smad7 in TGF-beta-mediated negative regulation of gut inflammation, Trends Immunol, vol.25, pp.513-520, 2004. ,
Controlled production of stable heterologous proteins in Lactococcus lactis, Appl Environ Microbiol, vol.68, pp.3141-3147, 2002. ,
URL : https://hal.archives-ouvertes.fr/hal-02683132
HtrA is the unique surface housekeeping protease in Lactococcus lactis and is required for natural protein processing, Mol Microbiol, vol.35, pp.1042-51, 2000. ,
URL : https://hal.archives-ouvertes.fr/hal-02696130
Expression of the Staphylococcus aureus surface proteins HtrA(1) and HtrA(2) in Lactococcus lactis, Fems Microbiol Lett, vol.237, pp.279-88, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-02682532
, , 1984.
Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing, J Bacteriol, vol.154, pp.1-9, 1983. ,
Quorum sensingcontrolled gene expression in lactic acid bacteria, J Biotechnol, vol.64, pp.15-21, 1998. ,
Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli, J Immunol, vol.172, pp.4535-4579, 2004. ,
Controlled intra-or extracellular production of staphylococcal nuclease and ovine omega interferon in Lactococcus lactis, FEMS Microbiol Lett, vol.224, pp.307-320, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-02679203
Cloning of Usp45, a gene encoding a secreted protein from lactococcuslactis subsp lactis Mg1363, Gene, vol.95, pp.155-60, 1990. ,
Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin, Appl Environ Microbiol, vol.62, pp.3662-3669, 1996. ,
Current and emerging drugs for the treatment of inflammatory bowel disease, Drug Des Devel Ther, vol.5, pp.185-210, 2011. ,
Interleukin-10 and the interleukin-10 receptor, Annu Rev Immunol, vol.19, pp.683-765, 2001. ,
Interleukin-10-deficient mice develop chronic enterocolitis, Cell, vol.75, pp.263-74, 1993. ,
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group, Gastroenterology, vol.119, pp.1473-82, 2000. ,
The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10, J Immunol, vol.166, pp.7625-7658, 2001. ,
IL-10 gene therapy prevents TNBS-induced colitis, Gene Ther, vol.9, pp.1715-1736, 2002. ,
Interleukin 10 gene transfer prevents experimental colitis in rats, Gut, vol.46, pp.344-353, 2000. ,
Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis, Gut, vol.52, pp.981-988, 2003. ,
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis, Nature, vol.389, pp.737-779, 1997. ,
Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells, Am J Pathol, vol.162, pp.597-608, 2003. ,
Transforming growth factor beta1 ameliorates intestinal epithelial barrier disruption by Cryptosporidium parvum in vitro in the absence of mucosal T lymphocytes, Infect Immun, vol.68, pp.5635-5679, 2000. ,
Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability, Am J Pathol, vol.167, pp.1587-97, 2005. ,
Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family, Biochimie, vol.90, pp.284-95, 2008. ,
Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions, Am J Respir Cell Mol Biol, vol.8, pp.439-484, 1993. ,
Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway, J Biol Chem, vol.281, pp.34730-34735, 2006. ,
Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract, Int J Food Microbiol, vol.144, pp.29-34, 2010. ,
, Submit your next manuscript to BioMed Central and take full advantage of: ? Convenient online submission ? Thorough peer review ? No space constraints or color figure charges ? Immediate publication on acceptance ? Inclusion in PubMed, CAS, Scopus and Google Scholar ? Research which is freely available for redistribution Submit your manuscript at www